[Ototoxicity of cisplatin in children with malignant diseases].
Ten out of 20 children with malignant diseases who received cisplatin in combination with other drugs developed hearing impairment primarily at the higher and rarely also at the lower frequencies. The CDDP-ototoxicity was found to be dose-related and irreversible. Audiometric abnormalities were symmetrical and bilateral. Two patients had symptomatic hearing impairment. Ototoxicity was more severe with higher individual and higher cumulative doses. CNS-irradiation increases the ototoxic effect of CDDP. Audiometric testing at the beginning of chemotherapy and during chemotherapy is important to find out preexisting disturbances of hearing function and to recognize early developing hearing loss.
Hadjilaskari
P
P
Universitäts-Kinderklinik Berlin.
Fengler
R
R
Hartmann
R
R
Henze
G
G
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001301:Audiometry, Pure-Tone; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003638:Deafness / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D014012:Tinnitus / Q000139:chemically induced
D002945:Cisplatin
Ototoxizität von Cisplatin bei Kindern mit malignen Erkrankungen.